Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)

This is a single-center, non-profit observational study with two sequential phases: an initial retrospective phase followed by a prospective phase. Patients were enrolled during two consecutive, non-overlapping periods. The primary objective of the study is to derive a clinical predictive score for multidrug-resistant (MDR) pathogen-related pneumonia in patients diagnosed with pneumonia presenting to the Emergency Department and/or admitted to the hospital from the community.

NCT Number	NCT07425561
Lead Sponsor	Azienda Ospedaliero-Universitaria Careggi
Conditions	Pneumonia, Pneumonia - Bacterial, Multi Drug Resistant, Multi Drug Resistant Organisms, Emergency, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe
Enrollment	300 participants
Start Date	2022-01-01
Primary Completion	2026-02-01 (estimated)
Study Completion	2026-02-08 (estimated)
Updated on ClinicalTrials.gov	2026-02-23